Claudin-3 and −4 were frequently elevated in various cancers including pancreatic ductal adenocarcinoma [17], prostate, uterine, ovarian cancer [18], while hepatocellular and renal carcinomas expressed lower levels of claudins-4 and −5 [19]. Here, CLDN4 is linked to renal carcinoma.